Lupin Limited CEO Vinita Gupta recently spoke of a growing understanding among the US regulator and other stakeholders of the need to support viable pricing of generic drugs in order to avoid drug shortages.
Indian companies, which are among the largest suppliers of generic drugs to the US, have long been pointing to the need for customers to stop demanding lower product
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?